#Canada #Vancouver #GBM Health #Gene Bio Medical #Geno10X Bioscience

GBM Health Holding Scores Major Grant for Healthcare Innovation

Vancouver, BC - In a significant move aimed at bolstering advancements in healthcare, GBM Health Holding has proudly announced that its subsidiaries, Gene Biotechnology Enterprises Ltd (operating as Gene Bio Medical) and Geno10X Bioscience Inc, have been awarded a transformative grant totaling $1.5 million CAD from Innovate BC. This funding is part of Innovate BC's Ignite Program, which focuses on promoting innovative technologies that can lead to impactful solutions in clean technology and life sciences.

Pioneering Projects Supported by Grant

The awarded funds will fuel two cutting-edge initiatives that promise to make waves in the sectors of precision medicine and sustainable biotechnology.

1. Gene Bio Medical: AI-Driven Diagnostics

Gene Bio Medical is set to leverage this funding to advance an innovative AI-powered diagnostic platform. This platform aims to enhance the early detection of chronic diseases through the use of proprietary biomarker algorithms. The goal? To significantly improve patient outcomes while simultaneously lowering healthcare costs.

2. Geno10X Bioscience Inc: Sustainable Bioreactor Technology

On the other hand, Geno10X Bioscience Inc plans to utilize its portion of the grant to expand its sustainable bioreactor technology. This cutting-edge approach applies principles of synthetic biology to produce high-value pharmaceuticals, achieving an impressive 80% reduction in carbon emissions compared to traditional production methods.

Commitment to Human Health and Planetary Sustainability

"This recognition from Innovate BC underscores our commitment to resolving critical challenges that exist at the crossroads of human health and environmental sustainability," commented Jessica Hu, CEO of GBM Health Holding. She further emphasized that combining Gene Bio Medical's precision diagnostics with Geno10X's green biomanufacturing not only pushes scientific boundaries but also results in scalable solutions that benefit patients and the planet.

Strategic Impact and Market Potential

The project spearheaded by Gene Bio Medical aligns perfectly with British Columbia's burgeoning leadership in digital health, targeting potential applications across North America and the Asia-Pacific region. Meanwhile, the innovation from Geno10X is positioned to meet the urgent global demand for decarbonized drug production, a market anticipated to hit $30 billion by 2030. The realization of both initiatives is projected to generate high-value jobs within British Columbia and strengthen partnerships with academic institutions, including the University of British Columbia.

About GBM Health Holding

Based in Vancouver, GBM Health Holding is dedicated to pioneering innovations across fields such as precision medicine, genomics, and sustainable biotechnology. Through its subsidiaries like Gene Bio Medical and Geno10X, the company is expertly positioned to unify advanced research and development with commercial solutions that prioritize health equity and environmental stewardship.

For further insights into these transformative projects funded by Innovate BC, visit Innovate BC.